Skip to main content
Figure 2 | Journal of Hematology & Oncology

Figure 2

From: Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

Figure 2

BENC-511 suppresses AKT activation triggered by IGF-1. (A) Myeloma (RPMI-8226, JJN3, LP1 and OPM2) cells were starved overnight and then treated with 100 μM of S14161, 50 μM of BENC-511, or DMSO for 2 hours, followed by 100 ng/mL of IGF-1 for 15 minutes. After incubation, cells were harvested and total proteins were isolated. Expression of AKT, p-AKT (T308), p-AKT (S473), and GAPDH was measured by immunoblotting. (B) RPMI-8226 and OPM2 cells were treated with increasing concentration of BENC-511 for 0.5 or 1 hour, S14161 for 2 hours, followed by IGF-1 stimulation. Cells were then harvested and total proteins isolated. Expression of AKT, p-AKT (S473), and GAPDH was measured by immunoblotting. (C) OPM2 cells were starved overnight and then treated with BENC-511 (8 μM), or DMSO for the indicated time followed by 100 ng/mL IGF-1 or 50 ng/mL IL-6 for 15 minutes. After incubation, cells were harvested and total proteins isolated. Expressions of total AKT, p-AKT (S473), PARP, and GAPDH were measured by immunoblotting. T-AKT: total AKT.

Back to article page